Zacks Investment Research Downgrades Olympus Corp. (OCPNY) to Hold

Olympus Corp. (OTCMKTS:OCPNY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

According to Zacks, “OLYMPUS CORPORATION is a Japan-based company. The Company is engaged in the manufacturing and selling of precision machineries and instruments. The businesses of the Company include Imaging System Business, Medical Systems Business, Life Science Business, Information and Communication Business, and Others Business. Olympus has always been a company that makes people’s dreams come true through innovative products. Olympus cameras have always been at the leading edge of innovation. “

Shares of Olympus Corp. (OCPNY) opened at $38.29 on Friday. The company has a market capitalization of $13,121.64, a P/E ratio of 22.93, a P/E/G ratio of 3.47 and a beta of 1.07. Olympus Corp. has a 12 month low of $33.17 and a 12 month high of $39.49. The company has a quick ratio of 1.28, a current ratio of 1.78 and a debt-to-equity ratio of 0.54.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at

About Olympus Corp.

Olympus Corporation is engaged in the manufacture and sale of precision machineries and instruments. The Company’s segments include Medical Business, Scientific Solutions Business, Imaging Business and Others. The Company’s Medical Business manufactures and sells medical endoscopes, surgical endoscopes, endotherapy devices and other products.

Receive News & Ratings for Olympus Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olympus Corp. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply